Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.

BMC Cancer · 2015 · PMC4413536 · PMID 25925846

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The current study results are in line with those of an AXIS subgroup analysis, which showed a trend toward longer PFS for patients who received axitinib after ≥9 months of sunitinib [ 20 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.